Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Basal Cell 2Melanoma 1

Interventions

Nivolumab 7cemiplimab 6Specimen Handling 5HhAntag691 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Biopsy 4sonidegib 3pembrolizumab 3CTLA-4 Antigen 3relatlimab 2prednylidene 2deltacortene 2daromun 2Surgical Procedures, Operative 2Standard of Care 2Prednisone 2Observation 2Aminolevulinic Acid 2tocilizumab 1talimogene laherparepvec 1poly ICLC 1flt3 ligand protein 1X-Rays 1Watchful Waiting 1Vitamin D 1Tomography, Optical Coherence 1Therapeutics 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × daromun × 1 year × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT07227870 2026-03-09

L19IL2/TNF in Patients With Basal Cell Carcinoma

Philogen S.p.A.

Phase 2 Not yet recruiting
92 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡